Gelesis Holdings PE Ratio 2021-2022 | GLS

Current and historical p/e ratio for Gelesis Holdings (GLS) from 2021 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Gelesis Holdings PE ratio as of November 25, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Gelesis Holdings PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-11-25 0.38 0.00
2022-09-30 1.08 $-0.87 0.00
2022-06-30 1.55 $-0.87 0.00
2022-03-31 4.53 $-0.70 0.00
2021-12-31 9.96 0 0.00
2021-09-30 9.92 0 0.00
2021-06-30 9.79 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.028B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.477B 10.28
GSK (GSK) United Kingdom $69.125B 8.67
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
QIAGEN (QGEN) Netherlands $11.120B 18.98
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Arcus Biosciences (RCUS) United States $1.934B 29.03
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
Zymeworks (ZYME) Canada $0.494B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00